Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

DAWN MERRITT

Allopathic & Osteopathic Physicians Dermatology

NPI
1750573986
CMS profile
260977
Location
ATHENS, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$69,797.27

160 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

By paying entity

PY2021 · entire year · sorted by reported total

Page 2 of 4; records 51–100 of 160 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

DAWN MERRITT

NPI 1750573986 · CMS profile ID 260977

Allopathic & Osteopathic Physicians / Dermatology

ATHENS, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 4; records 51–100 of 160 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1750573986?year=2021&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
DAWN MERRITT, NPI 1750573986, CMS profile ID 260977. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 160 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1750573986?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). DAWN MERRITT, NPI 1750573986, CMS profile ID 260977. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 160 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1750573986?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
DAWN MERRITT, NPI 1750573986, CMS profile ID 260977, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 4; records 51–100 of 160 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1750573986?year=2021&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

160 matching records · $69,797.27 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 160 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 160.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AbbVie Inc. $20.6609/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795941345 CMS
Lilly USA, LLC $900.0009/30/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819057305 CMS
Janssen Biotech, Inc. $6.3409/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788643167 CMS
Lilly USA, LLC $450.0009/13/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819062201 CMS
PFIZER INC. $13.1509/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833257747 CMS
Novartis Pharmaceuticals Corporation $17.9709/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813226059 CMS
Amgen Inc. $2,400.0009/06/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826325399 CMS
Amgen Inc. $400.0009/06/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826325403 CMS
AbbVie Inc. $28.1109/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795941341 CMS
Amgen Inc. $104.1609/03/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826325395 CMS
Lilly USA, LLC $11.1408/31/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819061457 CMS
Janssen Biotech, Inc. $2.3708/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788643163 CMS
Janssen Biotech, Inc. $22.1208/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788643165 CMS
Novartis Pharmaceuticals Corporation $2,700.0008/25/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813226019 CMS
Amgen Inc. $125.0008/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826325391 CMS
Janssen Biotech, Inc. $2.0008/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788643125 CMS
AbbVie Inc. $21.4908/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795941337 CMS
Janssen Biotech, Inc. $2.0908/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788643127 CMS
AbbVie Inc. $19.4608/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795941333 CMS
Novartis Pharmaceuticals Corporation $17.9508/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813226055 CMS
Janssen Biotech, Inc. $2.3008/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788643129 CMS
Janssen Biotech, Inc. $14.1208/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788643131 CMS
Lilly USA, LLC $1,800.0008/06/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819054091 CMS
Lilly USA, LLC $1,125.0008/06/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819065907 CMS
Lilly USA, LLC $972.6308/04/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818913319 CMS
Lilly USA, LLC $42.7508/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819054070 CMS
Lilly USA, LLC $24.5608/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819057303 CMS
AbbVie Inc. $20.2607/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795941329 CMS
PFIZER INC. $9.6607/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832960877 CMS
UCB, Inc. $1,770.0007/29/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807472367 CMS
UCB, Inc. $1,770.0007/29/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807472403 CMS
Novartis Pharmaceuticals Corporation $15.3007/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813226051 CMS
Janssen Biotech, Inc. $2.6207/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788643123 CMS
Lilly USA, LLC $900.0007/19/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819050287 CMS
Janssen Biotech, Inc. $20.0207/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788643121 CMS
UCB, Inc. $11.1107/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807378885 CMS
Lilly USA, LLC $27.6607/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 856542101 CMS
Novartis Pharmaceuticals Corporation $2.6707/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813226047 CMS
UCB, Inc. $1,770.0007/09/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807471657 CMS
Janssen Biotech, Inc. $14.1207/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788643161 CMS
AbbVie Inc. $13.8307/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795941325 CMS
Regeneron Healthcare Solutions, Inc. $20.3006/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 809620575 CMS
Janssen Biotech, Inc. $1.9106/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788643159 CMS
Janssen Biotech, Inc. $12.7606/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788643157 CMS
Novartis Pharmaceuticals Corporation $17.1706/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813226043 CMS
Lilly USA, LLC $900.0006/11/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819054087 CMS
AbbVie Inc. $19.4306/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795941321 CMS
Janssen Biotech, Inc. $17.7006/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788643155 CMS
Janssen Biotech, Inc. $0.8606/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788643153 CMS
UCB, Inc. $2,360.0006/03/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807418003 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $197,720.46 284
PY2020 $59,248.64 78
PY2021 $69,797.27 160
PY2022 $126,139.14 183
PY2023 $169,401.24 190
PY2024 $124,795.75 144
PY2025 $96,658.88 107

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $864.60 1
PY2025 Principal investigator $27,026.65 16
PY2024 Recipient $324.09 1
PY2024 Principal investigator $139,695.92 91
PY2023 Recipient $13,304.00 1
PY2023 Principal investigator $124,839.79 140
PY2022 Principal investigator $60,691.03 51
PY2021 Principal investigator $22,964.56 20
PY2020 Recipient $1,500.00 1
PY2020 Principal investigator $55,574.00 33
PY2019 Principal investigator $28,251.00 23

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

17 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Janssen Research & Development, LLC $1,986.00 12/19/2025 Non-covered Recipient Entity
MERRITT BIOSCIENCES LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175427411
Principal investigator 1 Janssen Research & Development, LLC $1,562.00 09/29/2025 Non-covered Recipient Entity
MERRITT BIOSCIENCES LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175427380
Principal investigator 1 Incyte Corporation $1,200.00 09/25/2025 Non-covered Recipient Entity
OAKVIEW DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1240567527
Principal investigator 1 Incyte Corporation $1,000.00 09/17/2025 Non-covered Recipient Entity
OAKVIEW DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1240567509
Principal investigator 1 Incyte Corporation $1,500.00 09/17/2025 Non-covered Recipient Entity
OAKVIEW DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1240567521
Principal investigator 1 Janssen Research & Development, LLC $204.00 08/22/2025 Non-covered Recipient Entity
MERRITT BIOSCIENCES LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175427372
Principal investigator 1 Janssen Research & Development, LLC $2,376.00 06/27/2025 Non-covered Recipient Entity
MERRITT BIOSCIENCES LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175427385
Principal investigator 1 Incyte Corporation $600.00 06/20/2025 Non-covered Recipient Entity
OAKVIEW DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1240567502
Principal investigator 1 Janssen Research & Development, LLC $3,088.00 04/28/2025 Non-covered Recipient Entity
MERRITT BIOSCIENCES LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175427392
Principal investigator 1 Eli Lilly and Company $2,700.00 04/11/2025 Non-covered Recipient Entity
OAKVIEW DERMATOLOGY, LLC
PSOSA (PSORIASIS SPECIAL AREAS) - A US-BASED, SINGLE-ARM, PROSPECTIVE, MULTICENTER, OBSERVATIONAL STUDY OF NAIL AND SCALP PSORIASIS IMPROVEMENT IN PATIENTS TREATED WITH IXEKIZUMAB No dispute reported 06/30/2026 1187887370
Principal investigator 1 Janssen Research & Development, LLC $1,500.00 03/24/2025 Non-covered Recipient Entity
MERRITT BIOSCIENCES LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1175427369
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $398.75 03/19/2025 Non-covered Recipient Entity
OAKVIEW DERMATOLOGY
A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS No dispute reported 06/30/2026 1184174280
Principal investigator 1 Janssen Research & Development, LLC $198.00 03/07/2025 Non-covered Recipient Entity
MERRITT BIOSCIENCES LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175427404
Recipient Novartis Pharmaceuticals Corporation $864.60 03/07/2025 Covered Recipient Physician Research Publication/Writing Support No dispute reported 06/30/2026 1190292274
Principal investigator 1 Incyte Corporation $2,574.90 03/03/2025 Non-covered Recipient Entity
OAKVIEW DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1240567491
Principal investigator 1 Janssen Research & Development, LLC $1,819.00 02/07/2025 Non-covered Recipient Entity
MERRITT BIOSCIENCES LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175427397
Principal investigator 1 Novartis Pharmaceuticals Corporation $4,320.00 01/01/2025 Non-covered Recipient Entity
OAKVIEW DERMATOLOGY LLC
A Multicenter, Double-blind, Placebo-controlled, Randomized Withdrawal and Open-label Extension Study Followed by Long-term Open-label Treatment Cycles to Assess the Efficacy, Safety and Tolerability of Remibrutinib (LOU064) in Adult Chronic Spontaneous U No dispute reported 06/30/2026 1190311909